P4‐206: FULL GENOMIC ANALYSIS OF ANAVEX ® 2‐73 PHASE 2A ALZHEIMER'S DISEASE STUDY IDENTIFIES BIOMARKERS ENABLING TARGETED THERAPY AND A PRECISION MEDICINE APPROACH

Gender Male 10 26,32% 9 29,03% 0.99x 0.87 (0.31-2.56) Female 28 73,68% 22 70,97% Fmily History Yes 9 23,68% 11 35,48% 0.30x 1.77 (0.65-5.14) No 29 76,32% 20 64,52% Schooling Illiterate 5 13,16% 5 16,13% 3.57# 4 12 a 42 grade 19 50,00% 11 35,48% 52 a 82 grade 6 15,79% 10 32,26% Incomplete High School 3 7,89% 1 3,23% Complete High School 0 0,00% 0 0,00% Incomplete Higher Education 0 0,00% 0 0,00% Complete Higher Education 5 13,16% 4 12,90% Age 50-59 years 0 0,00% 0 0,00% 1.26# 2 60-69 years 7 18,42% 3 9,68% 70-79 years 14 36,84% 11 35,48% 80-89 years 17 44,74% 17 54,84% 90 or more 0 0,00% 0 0,00% Caregiver Yes 27 71,05% 26 83,87% 0.26x 2.12 (0.65-6.20) No 11 28,95% 5 16,13% EVA Yes 4 10,53% 3 9,68% 0.99x 0.91 (0.22-3.63) No 34 89,47% 28 90,32% TBI Yes 1 2,63% 1 3,23% 0.99x 0.81 (0.04-15.87) No 37 97,37% 30 96,77% Smoking Yes 1 2,63% 8 25,81% 0.008x 12.87 (1.99-1.46) No 37 97,37% 23 74,19% Alcoholism Yes 0 0,00% 4 12,90% 0.03x No 38 100,00% 27 87,10% Physical Activity Yes 4 10,53% 5 16,13% 0.72x 1.64 (0.42-5.71) No 34 89,47% 26 83,87% Depression Yes 15 39,47% 15 48,39% 0.48x 1.44 (0.55-3.83) No 23 60,53% 16 51,61% Cardiovascular Disease Yes 23 60,53% 17 54,84% 0.80x 0.79 (0.30-2.09) No 15 39,47% 14 45,16% Comorbidities (3 or more) 0,00% 0,00% Yes 21 55,26% 9 29,03% 0.05x 0.33 (0.12-0.89) No 17 44,74% 22 70,97% B12 Vitamin 0,00% 0,00% Yes 3 7,89% 12 38,71% 0.002x 7.37 (1.82-26.07) No 35 92,11% 19 61,29% Therapy 0,00% 0,00% Rivastigmine 4 10,53% 2 6,45% 20,41# 3 Donepezil 3 7,89% 18 58,06% Galantamine 22 57,89% 8 25,81% Association 9 23,68% 3 9,68% Poster Presentations: Wednesday, July 25, 2018 S1519